NPI Targeting Gets the Message to the Right Physician. It Has No Say in When They Receive It.

The targeting problem in EHR pharmaceutical messaging gets solved before the harder problem is named. Pharma teams and platform vendors have invested considerably in NPI-level audience precision: specialty verification, historical prescribing data, practice setting, panel composition. Those capabilities are real, and they represent genuine progress over ZIP-code-level audience approximations. The framing that follows is that better NPI targeting in pharma produces better HCP engagement. The data has not consistently supported that conclusion, and the reason is not that NPI targeting is insufficient. It is that targeting and timing are separate problems, and only one of them has been seriously addressed. 

Precision and relevance are not synonyms 

NPI targeting answers a specific question: is this physician an appropriate audience for this message? Specialty code, historical prescribing volume, patient demographics — these are population-level attributes of the physician that persist across every patient encounter they conduct. A correctly targeted message is one delivered to a physician who could plausibly prescribe the drug in question. That is a necessary condition for relevance. It is not sufficient. 

A cardiologist receiving a heart failure messaging campaign has been correctly targeted. If that message surfaces while they review a colonoscopy referral or close out documentation after an encounter that ended an hour ago, the targeting was sound and the delivery was irrelevant. In session-based EHR point-of-care messaging, those two things coexist regularly. 

Why the conflation persists 

The gap between audience precision and contextual relevance is difficult to surface in standard reporting. NPI match rates, specialty verification percentages, and historical prescribing alignment are all measurable. They appear in campaign performance decks as evidence that the targeting layer is working. What does not appear is any measure of whether the message arrived during a clinically relevant encounter, because a session-based system has no visibility into what the physician was doing when the chart opened. 

Pharma buyers receive detailed targeting reports while the timing problem stays unmeasured and, by extension, unaddressed. A campaign can show a 92% NPI match rate and a 1.4% engagement rate in the same row of data. The targeting report does not explain the engagement number. It describes the population. It says nothing about the moment. 

Writing in Pharmaceutical Executive  in December 2025, OptimizeRx Chief Product and Technology Officer Doug Besch described the pattern directly: campaigns built on NPI lists focus on "breadth of reach, often sacrificing personalization," and as a result, "a significant portion of these campaigns rarely intersect with the clinical realities that shape day-to-day decision-making." That observation comes from a platform operating inside EHR workflows. The mismatch is not theoretical. 

Veeva Pulse Field Trends data from Q1 2025  shows that field teams share materials in fewer than half of HCP interactions, with nearly 80% of approved content rarely or never used — despite content-driven engagement doubling treatment starts when it lands correctly. That gap between content availability and clinical relevance in field interactions is amplified, not resolved, by digital delivery that does not account for the clinical moment. 

What NPI data cannot see 

An NPI record tells you who a physician is. It does not tell you what they are doing right now. The prescribing moment for a branded GLP-1 agonist during a newly diagnosed type 2 diabetes encounter is not a property of the endocrinologist. It is a property of the encounter currently open on their screen. NPI targeting has no mechanism for detecting it.

This distinction matters more in EHR environments than in any other pharmaceutical marketing channel, because the EHR is where the prescribing decision actually happens. A correctly targeted display ad on a medical news site fails to reach the physician at the moment of prescribing. A correctly targeted EHR message that fires at the wrong clinical moment does the same — in the one environment where timing could have made the delivery genuinely useful.

Swoop, a real-world data targeting company serving 42 of the top 50 pharmaceutical brands, acknowledged the limitation directly when framing its own beyond-NPI product: "suboptimal HCP response rates and ROI associated with traditional, volume-based 1:1 NPI targeting" are the baseline the industry is trying to improve on. Improving the audience model is one path forward. Improving the trigger architecture is another, and for EHR messaging specifically, it is the more consequential one.

Where the engagement ceiling sits 

When delivery timing is low-relevance by default, the ceiling on engagement is set by the trigger architecture, not the targeting quality. Tightening the audience does not raise that ceiling. It reduces wasted impressions within it. A campaign targeting 40,000 physicians instead of 400,000 still delivers every message at a chart-open event. The encounter contexts behind those events are no more clinical than they were at the larger scale.

This explains a pattern pharma point-of-care teams know well: engagement rates that plateau after audience optimization. At some point, the remaining variance in engagement is not explained by who receives the message. It is explained by when. A platform that improves session-based targeting is optimizing within a constraint it has not acknowledged.

The physician engagement problem in EHR pharmaceutical messaging involves two separate failure modes. One is reaching the wrong physician. The other is reaching the right physician at the wrong clinical moment. NPI targeting addresses the first. The second requires a different infrastructure decision — one about what event triggers delivery, not which physicians are eligible to receive it.

Frequently asked questions

Can NPI targeting and clinical trigger data work together? They can and should. NPI or specialty segmentation defines the eligible audience. A clinical trigger — a specific diagnosis code, a prescription event, an active medication review — determines which encounter within that audience qualifies for delivery. Targeting narrows the population. The trigger selects the moment. The two are complementary and address different parts of the relevance problem.

If engagement rates are low, how do you identify whether targeting or timing is the cause? A basic diagnostic is to segment engagement by session context: time of day, session duration, and whether an active prescription or diagnosis event was present. Session-triggered messages delivered during high-documentation periods — end-of-day chart cleanup — consistently underperform against messages delivered during active patient encounter windows. If the engagement gap tracks session context rather than physician specialty, the problem is timing. Tighter targeting will not close it.

Does action-triggered messaging still require specialty or NPI segmentation? Yes. A trigger without audience segmentation delivers a contextually relevant message to the wrong physician. A prescription event for a branded antihypertensive is a valid trigger. Delivering a co-pay message to a psychiatrist writing a beta-blocker for essential tremor is a trigger-only failure. Audience precision defines the eligible population. The clinical trigger defines the moment of delivery. Both are necessary, and neither replaces the other.

Spark delivers action-triggered, patient-personalised messages within EHR workflows at the precise moment of care. See how Spark works with your EHR platform.